BTG (LON:BTG) said today that the 1st batch of patients in the European Union were treated with its DC Bead Lumi radiopaque drug-eluting bead. Two patients were treated for hepatocellular carcinoma and 1 patient was treated for malignant colorectal cancer metastasized to the liver.
The bead, which is the 1st commercially available radiopaque drug-eluting bead in the EU, uses doxorubicin or irinotecan to locally treat tumors.
Get the full story at our sister site, Drug Delivery Business News.
The post First European patients treated with BTG’s drug-eluting bead appeared first on MassDevice.